1. Home
  2. TCBS vs SER Comparison

TCBS vs SER Comparison

Compare TCBS & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Texas Community Bancshares Inc.

TCBS

Texas Community Bancshares Inc.

N/A

Current Price

$17.40

Market Cap

50.6M

Sector

Finance

ML Signal

N/A

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

N/A

Current Price

$1.45

Market Cap

56.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TCBS
SER
Founded
1934
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
56.4M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
TCBS
SER
Price
$17.40
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
3.4K
★ 67.1K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
★ 1.37%
N/A
EPS Growth
★ 327.27
N/A
EPS
★ 0.86
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.35
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.72
$1.14
52 Week High
$20.00
$4.26

Technical Indicators

Market Signals
Indicator
TCBS
SER
Relative Strength Index (RSI) 56.60 34.54
Support Level $17.23 $1.33
Resistance Level $17.92 $2.13
Average True Range (ATR) 0.08 0.29
MACD 0.04 -0.01
Stochastic Oscillator 68.89 14.68

Price Performance

Historical Comparison
TCBS
SER

About TCBS Texas Community Bancshares Inc.

Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: